S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

ALGS Aligos Therapeutics Inc

40.3388

1.99 (5.19%)

21 Dec 2024 - Closed

Delayed by 15 minutes

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Aligos Therapeutics (NASDAQ:ALGS)
Historical Stock Chart
From Nov 2024 to Dec 2024

Click Here for more Aligos Therapeutics Charts.

Aligos Therapeutics (NASDAQ:ALGS)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more Aligos Therapeutics Charts.

Aligos Therapeutics Inc News

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Saturday 14 December 2024 (1 week ago) • GlobeNewswire Inc.

Aligos Therapeutics to Present at Investor Conferences in December
Wednesday 27 November 2024 (4 weeks ago) • GlobeNewswire Inc.

Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
Wednesday 20 November 2024 (1 month ago) • GlobeNewswire Inc.

Form EFFECT - Notice of Effectiveness
Tuesday 19 November 2024 (1 month ago) • Edgar (US Regulatory)

Form S-3 - Registration statement under Securities Act of 1933
Thursday 7 November 2024 (1 month ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 7 November 2024 (1 month ago) • Edgar (US Regulatory)

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
Thursday 7 November 2024 (1 month ago) • GlobeNewswire Inc.

Form 8-K - Current report
Thursday 7 November 2024 (1 month ago) • Edgar (US Regulatory)

Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024
Thursday 31 October 2024 (2 months ago) • GlobeNewswire Inc.

Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184
Tuesday 22 October 2024 (2 months ago) • GlobeNewswire Inc.

Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024
Wednesday 16 October 2024 (2 months ago) • GlobeNewswire Inc.

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Friday 11 October 2024 (2 months ago) • GlobeNewswire Inc.

More Aligos Therapeutics Inc News Articles

Australian SE All Ordina...

JP Morgan Chase

Australia And New Zealan...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions